Key facts
- This page summarizes Rita A. Karachun's Form 4 filing for Merck & Co., Inc. (MRK).
- 9 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 05 May 2023, 16:54.
Rita A. Karachun - 03 May 2023 Form 4 Insider Report for Merck & Co., Inc. (MRK)
- Reporting relationship
- Sr. VP Fince-Global Controller
- Issuer ticker
- MRK
- Reported as of
- 03 May 2023
- Net transaction value
- -$744,702
- SEC form
- 4
- Accepted by SEC
- 05 May 2023, 16:54:07 UTC
- Prior SEC filing
- 04 May 2023
- Next SEC filing
- 05 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Kelly E. W. Grez as Attorney-in-Fact for Rita Karachun
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Rita A. Karachun filed Form 4 for Merck & Co., Inc. (MRK) on 05 May 2023.
Change
- Previous filing in this sequence was filed on 04 May 2023.
- Current net transaction value: -$744,702.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MRK
transaction
Common Stock
Options Exercise
- Transaction value
- $94,666
- Shares
- +803
- Change %
- +1.8%
- Price
- $117.89
- Shares after
- 45,363
- Date
- 03 May 2023
- Ownership
- Direct
MRK
transaction
Common Stock
Tax liability
- Transaction value
- $32,538
- Shares
- -276
- Change %
- -0.61%
- Price
- $117.89
- Shares after
- 45,087
- Date
- 03 May 2023
- Ownership
- Direct
MRK
transaction
Common Stock
Options Exercise
- Transaction value
- $112,191
- Shares
- +949
- Change %
- +2.1%
- Price
- $118.22
- Shares after
- 46,036
- Date
- 04 May 2023
- Ownership
- Direct
MRK
transaction
Common Stock
Tax liability
- Transaction value
- $38,540
- Shares
- -326
- Change %
- -0.71%
- Price
- $118.22
- Shares after
- 45,710
- Date
- 04 May 2023
- Ownership
- Direct
MRK
transaction
Common Stock
Options Exercise
- Transaction value
- $985,361
- Shares
- +15,875
- Change %
- +35%
- Price
- $62.07
- Shares after
- 61,585
- Date
- 04 May 2023
- Ownership
- Direct
MRK
transaction
Common Stock
Sale
- Transaction value
- $1,865,843
- Shares
- -15,875
- Change %
- -26%
- Price
- $117.53
- Shares after
- 45,710
- Date
- 04 May 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MRK
transaction
Derivative
Restricted Stock Unit
Options Exercise
- Transaction value
- $0
- Shares
- -803
- Change %
- -33%
- Price
- $0.000000
- Shares after
- 1,608
- Date
- 03 May 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 803
- Exercise price
- Footnotes
- F2, F3
MRK
transaction
Derivative
Restricted Stock Unit
Options Exercise
- Transaction value
- $0
- Shares
- -949
- Change %
- -50%
- Price
- $0.000000
- Shares after
- 951
- Date
- 04 May 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 949
- Exercise price
- Footnotes
- F2, F4
MRK
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -15,875
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 04 May 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 15,875
- Exercise price
- $62.07
- Footnotes
- F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.5000 to $117.6200, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
Footnote F2
Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.
Footnote F3
These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/3/2023, 5/3/2024 and 5/3/2025.
Footnote F4
These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024.
Footnote F5
The option became exercisable in equal installments on 5/5/2018, 5/5/2019 and 5/5/2020.